GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Owner Earnings per Share (TTM)

3D Medicines (HKSE:01244) Owner Earnings per Share (TTM) : (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

3D Medicines does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.


The historical rank and industry rank for 3D Medicines's Owner Earnings per Share (TTM) or its related term are showing as below:



HKSE:01244's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.78
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

3D Medicines's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-1.65. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.52. It's PE Ratio ratio for today is At Loss.

3D Medicines's EPS without NRI for the six months ended in Dec. 2023 was HK$-1.53. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.20. It's PE Ratio without NRI ratio for today is At Loss.


3D Medicines Owner Earnings per Share (TTM) Historical Data

The historical data trend for 3D Medicines's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Owner Earnings per Share (TTM) Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
- - - -

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial - - - - -

Competitive Comparison of 3D Medicines's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, 3D Medicines's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Medicines's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Price-to-Owner-Earnings falls into.



3D Medicines Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

3D Medicines does not have enough data to calculate Owner Earnings per Share (TTM). Please check Wal-Mart Stores Inc, as your reference.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


3D Medicines Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


3D Medicines (HKSE:01244) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.
Executives
Gong Zhaolong 2101 Beneficial owner
Zhu Pai 2101 Beneficial owner
Dragon Prosper Holdings Limited 2101 Beneficial owner
Simcere Pharmaceutical Group Limited 2101 Beneficial owner
Gong Zhaolong 2501 Other
Immunal Medixin Us Limited 2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership) 2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd. 2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.) 2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership) 2201 Interest of corporation controlled by you
Zhu Jinqiao 2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines